TED Ted Baker Plc

RNS Number:9450D
Tepnel Life Sciences PLC
02 June 2006


              Tepnel Life Sciences plc ('Tepnel' or 'the Company')

                                Issue of equity


Manchester, UK, 02 June, 2006 - Tepnel Life Sciences PLC (AIM: TED), the
UK-based international Molecular Diagnostics and Research Products & Services
group, is pleased to announce that it has successfully raised #1.2m (before
expenses) by placing 17,034,160 new ordinary shares of 1p each ("Placing Shares
") at 7p per share with institutional shareholders ("the Placing").  These funds
will be used in part for the completion of the Company's new 18,000ft2 facility
in Livingston, Scotland and will also provide additional working capital as
required by an increase in sales.  This facility will allow for the
consolidation of operations in Edinburgh and Glasgow and will incorporate
pharmaceutical services including high throughput genotyping and protein
analysis.

4,258,540 warrants to subscribe for 4,258,540 new ordinary shares of 1p each are
being made available under the Placing on the basis of one warrant for every
four Placing Shares subscribed for under the Placing ("Warrants").  The Warrants
are exercisable at any time up to the fifth anniversary of admission on the
Placing Shares to trading on AIM at a price of 8.05p per Warrant.  The Warrants
will not be listed on AIM or any other stock exchange.

Ben Matzilevich, CEO commented "We are executing against our strategic plan.  We
continue to improve our results while increasing our market share with major UK
pharmaceutical companies.  This facility in Scotland is an essential component
of the long term strategy and should also allow us to offer gene analysis,
sequencing and proteomics."

Application has been made for the admission of the Placing Shares to trading on
the AIM market of the London Stock Exchange on 6 June 2006.  The Placing Shares
will rank pari passu with the existing ordinary shares of the Company.


                                    - ends -


Enquiries:

For Further Information:

Tepnel Life Sciences plc
Ben Matzilevich, CEO
0161 946 2200

De Facto Communications
Richard Anderson
020 7861 3838

Notes to Editors

About Tepnel Life Sciences plc

Tepnel is a UK-based international life sciences company focused on molecular
diagnostics and research products and services including DNA purification kits
and reagents, scientific services for nucleic acid purification, drug analysis,
genotyping and genetically modified foods. Tepnel was founded in 1992 to exploit
DNA technology generated at UMIST (University of Manchester Institute of Science
and Technology) and is quoted on the AIM market of the London Stock Exchange
(AIM: TED). More information on Tepnel can be found at www.tepnel.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

IOEDFLFBQQBZBBE

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024

Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024